

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptaul29pxo

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	May 12	EXTEND option available in structure searching
NEWS	4	May 12	Polymer links for the POLYLINK command completed in REGISTRY
NEWS	5	May 27	New UPM (Update Code Maximum) field for more efficient patent SDIs in CAplus
NEWS	6	May 27	CAplus super roles and document types searchable in REGISTRY
NEWS	7	Jun 28	Additional enzyme-catalyzed reactions added to CASREACT
NEWS	8	Jun 28	ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG, and WATER from CSA now available on STN(R)
NEWS	9	Jul 12	BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS
NEWS	10	Jul 30	BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting
NEWS	11	AUG 02	IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields
NEWS	12	AUG 02	CAplus and CA patent records enhanced with European and Japan Patent Office Classifications
NEWS	13	AUG 02	STN User Update to be held August 22 in conjunction with the 228th ACS National Meeting
NEWS	14	AUG 02	The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available
NEWS	15	AUG 04	Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004
NEWS	16	AUG 27	BIOCOMMERCE: Changes and enhancements to content coverage
NEWS	17	AUG 27	BIOTECHABS/BIOTECHDS: Two new display fields added for legal status data from INPADOC
NEWS	18	SEP 01	INPADOC: New family current-awareness alert (SDI) available
NEWS	19	SEP 01	New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!
NEWS	20	SEP 01	New display format, HITSTR, available in WPIDS/WPINDEX/WPIX
NEWS	21	SEP 14	STN Patent Forum to be held October 13, 2004, in Iselin, NJ
NEWS EXPRESS		JULY 30	CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:31:03 ON 20 SEP 2004

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 12:31:16 ON 20 SEP 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 SEP 2004 HIGHEST RN 748118-51-6

DICTIONARY FILE UPDATES: 19 SEP 2004 HIGHEST RN 748118-51-6

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>


Uploading C:\STNEXP4\QUERIES\759a.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 H,Ak
G2 O,N,C

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 12:31:38 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 8311 TO ITERATE

12.0% PROCESSED 1000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 160757 TO 171683
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> search l1

ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:.
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:full
FULL SEARCH INITIATED 12:31:48 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 166269 TO ITERATE

100.0% PROCESSED 166269 ITERATIONS
SEARCH TIME: 00.00.10

39 ANSWERS

L3 39 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

155.42

155.63

FILE 'CAPLUS' ENTERED AT 12:32:09 ON 20 SEP 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Sep 2004 VOL 141 ISS 13

FILE LAST UPDATED: 19 Sep 2004 (20040919/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13

L4 14 L3

=> d 14 fbib ab hitstr 1-14

L4 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:767317 CAPLUS

DN 139:381230

TI Hydroformylation Reactions with Recyclable Rhodium-Complexed Dendrimers on a Resin

AU Lu, Shui-Ming; Alper, Howard

CS Centre for Catalysis Research and Innovation, Department of Chemistry, University of Ottawa, Ottawa, ON, K1N 6N5, Can.

SO Journal of the American Chemical Society (2003), 125(43), 13126-13131
CODEN: JACSAT; ISSN: 0002-7863

PB American Chemical Society

DT Journal

LA English

OS CASREACT 139:381230

AB Rhodium-complexed dendrimers supported on a resin were evaluated as catalysts for the hydroformylation of aryl olefins and vinyl esters. The results showed the reactions proceeded very efficiently at room temperature with

excellent yields. Outstanding selectivity for the branched aldehydes was also observed in all cases. The dendritic catalysts can be recycled by simple filtration and reused even up to the tenth cycle without loss of activity and selectivity. These results represent a dramatic improvement over those previously described for rhodium-catalyzed (dendrimer and nondendrimer based) hydroformylation reactions.

IT 624735-07-5DP, resin-bound, reaction products with diphenylphosphine and formaldehyde followed by bis(chlorodicarbonylrhodium)

RL: CAT (Catalyst use); SPN (Synthetic preparation); PREP (Preparation);
USES (Uses)


(dendrimer; preparation of recyclable rhodium-complexed dendrimers on resin
as catalysts for regioselective hydroformylation of aryl olefins)

RN 624735-07-5 CAPLUS


CN Glycine, N-[3,5-bis[[(2S)-2,6-bis[[(9H-fluoren-9-ylmethoxy) carbonyl] amino]-
1-oxohexyl] amino] benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



IT 624735-07-5P 624735-09-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)


(preparation of recyclable rhodium-complexed dendrimers on resin as
catalysts for regioselective hydroformylation of aryl olefins)

RN 624735-07-5 CAPLUS


CN Glycine, N-[3,5-bis[[[(2S)-2,6-bis[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-1-oxohexyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





PAGE 2-A



RN 624735-09-7 CAPLUS

CN Glycine, N-[3,5-bis[[[(2S)-2,6-bis[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-1-oxohexyl]amino]benzoyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:960938 CAPLUS
DN 138:337781
TI Efficient synthesis of a new potential chelating agent for
radioimmunotherapy
AU Gouin, Sebastien G.; Gestin, Jean-Francois; Remaud, Patricia;
Faivre-Chauvet, Alain; Meslin, Jean Claude; Deniaud, David
CS Laboratoire de Synthèse Organique, UMR CNRS 6513, Faculté des Sciences et
des Techniques, Nantes, 44072, Fr.
SO Synlett (2002), (12), 2080-2082

CODEN: SYNLES; ISSN: 0936-5214

PB Georg Thieme Verlag

DT Journal

LA English

OS CASREACT 138:337781

AB The synthesis of a new rigid analog of cyclohexyl-TTHA, an efficient lanthanide ligand, as well as the first complexation trials are reported. This polyaminopolycarboxylic acid (I) was obtained in five steps from o-phenylenediamine as starting product. The key intermediate was tetramine II, which after alkylation and hydrolysis gave I with ten coordination centers.


IT **518038-50-1P 518038-51-2P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of polyaminopolycarboxylic acid and its complexation with yttrium)


RN 518038-50-1 CAPLUS

CN Carbamic acid, [1,2-phenylenebis(imino(2-oxo-2,1-ethanediyl))]bis-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)



RN 518038-51-2 CAPLUS

CN Carbamic acid, [1,2-phenylenebis(imino(2-oxo-2,1-ethanediyl))]bis-, bis(9H-fluoren-9-ylmethyl) ester (9CI) (CA INDEX NAME)



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:695943 CAPLUS
 DN 137:216780
 TI Preparation of aromatic carboxamides as modulators of receptor for
 advanced glycated end products (RAGE).
 IN Mjalli, Adnan M. M.; Andrews, Rob; Wysong, Christopher
 PA Transtech Pharma, Inc., USA
 SO PCT Int. Appl., 95 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002070473	A2	20020912	WO 2002-US6707	20020305
	WO 2002070473	A3	20021227		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
				US 2001-273403P	P 20010305
				US 2001-273404P	P 20010305
				US 2001-273429P	P 20010305
				US 2001-273445P	P 20010305
				US 2001-273446P	P 20010305
				US 2001-273454P	P 20010305
				US 2001-273455P	P 20010305
	US 2002193432	A1	20021219	US 2002-91759	20020305
				US 2001-273403P	P 20010305
				US 2001-273404P	P 20010305
				US 2001-273429P	P 20010305
				US 2001-273445P	P 20010305
				US 2001-273446P	P 20010305
				US 2001-273454P	P 20010305
				US 2001-273455P	P 20010305
	EP 1377295	A2	20040107	EP 2002-713758	20020305
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
				US 2001-273403P	P 20010305
				US 2001-273404P	P 20010305
				US 2001-273429P	P 20010305
				US 2001-273445P	P 20010305
				US 2001-273446P	P 20010305
				US 2001-273454P	P 20010305
				US 2001-273455P	P 20010305
				WO 2002-US6707	W 20020305

OS MARPAT 137:216780
 AB G2R1R2CG1CONR3R4 [I; G1 = alkylene; G2 = H, alkyl, aryl, alkylaryl, amino, (substituted) imidazolyl; R1 = H, alkyl, aryl, alkylaryl; R2 = alkyl, aryl, aralkyl, etc.; R3 = H, alkyl, alkylaryl, alkoxyaryl; R4 = alkylaryl, alkoxyaryl, aryl], were prepared I are modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, β -amyloid and amphoterin. I are useful in

treating inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis. Thus, 3-(3-tert-butoxyphenyl)-3-(9-fluorenylmethoxycarbonylamino)propionic acid, HTBU, diisopropylethylamine, and 2,4-bis-(3-diethylaminopropoxy)aniline (preparation given) were stirred overnight in MeCN to give 3-(3-tert-butoxyphenyl)-3-(9-fluorenylmethoxycarbonylamino)propionic acid 2,4-bis-(3-diethylaminopropoxy)aniline amide. The latter showed $IC_{50} < 0.5 \mu M$ for inhibition of binding of RAGE to s100b.

IT 457060-71-8P 457060-72-9P 457060-73-0P
457060-75-2P 457060-76-3P 457060-78-5P
457060-79-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aromatic carboxamides as modulators of receptor for advanced glycated end products (RAGE))


RN 457060-71-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[3-[[2-butoxy-4-[3-(diethylamino)propoxy]phenyl]amino]-2-[[[9H-fluoren-9-ylmethoxy)carbonyl]amino]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 457060-72-9 CAPLUS
CN Carbamic acid, [2-[[2-butoxy-4-[3-(diethylamino)propoxy]phenyl]amino]-2-oxo-1-(4-piperidinylmethyl)ethyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 457060-73-0 CAPLUS
CN Carbamic acid, [2-[[2-butoxy-4-[3-(diethylamino)propoxy]phenyl]amino]-2-oxo-1-[[1-(phenylmethyl)-4-piperidinyl]methyl]ethyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)



PAGE 1-A





PAGE 2-A





RN 457060-75-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[3-[[2-butoxy-4-[3-(diethylamino)propoxy]phenyl]amino]-2-[[(9H-fluoren-9-ylmethoxy) carbonyl]amino]-3-oxopropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)





RN 457060-76-3 CAPLUS
 CN Carbamic acid, [1-[(1-benzoyl-4-piperidinyl)methyl]-2-[[2-butoxy-4-[3-(diethylamino)propoxy]phenyl]amino]-2-oxoethyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)



RN 457060-78-5 CAPLUS
 CN 1-Piperidinecarboxylic acid, 3-[3-[[2-butoxy-4-[3-(diethylamino)propoxy]phenyl]amino]-2-[[(9H-fluoren-9-ylmethoxy) carbonyl]amino]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI)
 (CA INDEX NAME)



RN 457060-79-6 CAPLUS
 CN Carbamic acid, [2-[[2-butoxy-4-[3-(diethylamino)propoxy]phenyl]amino]-2-oxo-1-(3-piperidinylmethyl)ethyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:462923 CAPLUS
 DN 137:241208
 TI Introduction of Lanthanide(III) Chelates to Oligopeptides on Solid Phase
 AU Peuralahti, Jari; Hakala, Harri; Mukkala, Veli-Matti; Loman, Kristiina;
 Hurskainen, Pertti; Mulari, Outi; Hovinen, Jari
 CS PerkinElmer Life Sciences Wallac Oy, Turku, FIN-20101, Finland
 SO Bioconjugate Chemistry (2002), 13(4), 870-875
 CODEN: BCCHES; ISSN: 1043-1802
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 137:241208
 AB The synthesis of oligopeptide building blocks for the introduction of
 nonluminescent and luminescent lanthanide(III) chelates to the
 oligopeptide structure on the solid phase is described. The oligopeptide
 conjugates synthesized were used in DELFIA-based receptor binding assay
 (motilin) as well as in LANCE time-resolved fluorescence quenching assay
 (caspase-3).
 IT **450374-57-9P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT


(Reactant or reagent)

(preparation of nonluminescent and luminescent lanthanide(III) chelates and their incorporation in solid-phase peptide synthesis)


RN 450374-57-9 CAPLUS

CN 3-Oxa-6,9,12-triazatetradecan-14-oic acid, 6,9-bis[2-(1,1-dimethylethoxy)-2-oxoethyl]-12-[[4-[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]acetyl]amino]phenyl]methyl]-2,2-dimethyl-4-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2002:149241 CAPLUS

DN 136:340985

TI A Noncovalent Approach to Antiparallel β -Sheet Formation


AU Zeng, Huaqiang; Yang, Xiaowu; Flowers, Robert A., II; Gong, Bing

CS Department of Chemistry, Natural Sciences Complex, State University of New York, Buffalo, NY, 14260, USA

SO Journal of the American Chemical Society (2002), 124(12), 2903-2910
 CODEN: JACSAT; ISSN: 0002-7863
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 136:340985
 AB Four tripeptide chains, when attached to the same end of a hydrogen-bonded duplex peptides I·II (R = Me, iso-Bu; Ia has R = Me; Ib has R = iso-Bu; IIa has R = iso-Bu; IIb has R = Me) with the unsym., complementary sequences of ADAA/DADD, have been brought into proximity, leading to the formation of four hybrid duplexes, Ia·IIa, Ia·IIb, Ib·IIa, and Ib·IIb, each of which contains a two-stranded β -sheet segment. The extended conformations of the peptide chains were confirmed by 1D and 2D NMR. The peptide strands stay registered through hydrogen bonding and the β -sheets are stabilized by side chain interactions. Two-dimensional NMR data also indicate that the duplex template prevents further aggregation in the peptide segment. When the peptide chains are attached to the two different termini of the duplex template, NMR studies show the presence of a mixture with no clearly defined conformations. In the absence of the duplex template, the tripeptides are found to associate randomly. Finally, isothermal titration calorimetry studies revealed that the hybrid duplex Ia·IIa was more stable than either the duplex template or the peptides alone.

IT **416899-51-9P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of hydrogen-bonded duplex templates with peptide chains that form antiparallel β -sheet-like structures)


RN 416899-51-9 CAPLUS
 CN Benzoic acid, 3-[[[2-(octyloxy)-5-[(1-oxohexyl)amino]benzoyl]amino]acetyl]amino]-5-[[[(phenylmethoxy)carbonyl]amino]acetyl]amino]-, octyl ester (9CI) (CA INDEX NAME)



RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2000:553906 CAPLUS
 DN 133:335443
 TI Synthesis of model compounds for potential contrast agents containing phosphonate and peptide moieties
 AU Shalem, Hutti; Shatzmiller, Shimon; Feit, Ben-Ami
 CS School of Chemistry, The Raymond and Beverly Sackler Faculty of Exact Sciences, Tel Aviv University, Ramat Aviv, Tel Aviv-Jaffa, 69978, Israel
 SO Perkin 1 (2000), (16), 2831-2837
 CODEN: PERKF9

PB Royal Society of Chemistry
 DT Journal
 LA English
 OS CASREACT 133:335443
 AB The synthesis of di-Me 2-acetoxy-2-(2,4-diiodo-5-aminophenyl)ethylphosphonate (I) and di-Me 2-acetoxy-2-(2,4,6-triiodo-3,5-diaminophenyl)ethylphosphonate (II) is described. Several amido derivs. III [X = CO(CH₂)_nCO; n = 0, 2, 4, 6] and peptide derivs. IV (R = Boc-Ala-Ala-, Cbz-Gly-Gly-, Cbz-Leu-Gly-, Cbz-Gly-Ala-, Cbz-Ala-Val-) of these phosphonates were prepared. These products are composed of a combination of structural/functional moieties which enable them to be potential nonionic, selective x-ray contrast agents.
 IT **303183-55-3P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of phosphonates and their peptide derivs. as potential nonionic, selective x-ray contrast agents)
 RN 303183-55-3 CAPLUS
 CN Carbamic acid, [[5-[1-(acetyloxy)-2-(dimethoxyphosphinyl)ethyl]-4,6-diiodo-1,3-phenylene]bis[imino(2-oxo-2,1-ethanediyl)]]bis-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2000:535988 CAPLUS
 DN 133:267133
 TI New highly potent dipeptidic growth hormone secretagogues with low molecular weight
 AU Peschke, Bernd; Ankersen, Michael; Hansen, Thomas Kruse; Hansen, Birgit Sehested; Lau, Jesper; Nielsen, Karin Kramer; Raun, Kirsten
 CS Health Care Chemistry, Novo Nordisk A/S, Malov, 2760, Den.
 SO European Journal of Medicinal Chemistry (2000), 35(6), 599-618
 CODEN: EJMCA5; ISSN: 0223-5234
 PB Editions Scientifiques et Medicales Elsevier
 DT Journal
 LA English
 AB Based on NN703, low mol. weight growth hormone secretagogues (GHSs) with a reduced number of hydrogen binding sites were designed by removal of the C-terminal amide group. The compds. were highly potent in combination with high efficacy in a rat pituitary cell assay, being characterized with EC50 values down to 0.8 nM. Selected compds. were tested in in vivo animal models. The oral bioavailability in dogs was 16-44%. Also, the ED50 values of the compds. were determined both in dog and swine.
 IT **202811-34-5P 202811-36-7P 202811-38-9P**
297175-37-2P 297175-40-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and biol. activity of highly potent dipeptidic growth hormone secretagogues with low mol. wts.)

RN 202811-34-5 CAPLUS


CN Carbamic acid, [2-[2-[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]acetyl]aminophenyl]ethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 202811-36-7 CAPLUS

CN Carbamic acid, [(1R)-2-[[2-[2-[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]acetyl]amino]phenyl]ethyl]methylamino]-1-(2-naphthalenylmethyl)-2-oxoethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 202811-38-9 CAPLUS
 CN Carbamic acid, [(3E)-5-[[[(1R)-2-[[2-[2-[[[(9H-fluoren-9-ylmethoxy) carbonyl] amino] acetyl] amino] phenyl] ethyl] methylamino]-1-(2-naphthalenylmethyl)-2-oxoethyl] methylamino]-1,1-dimethyl-5-oxo-3-pentenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


PAGE 1-A



PAGE 1-B




RN 297175-37-2 CAPLUS
 CN Carbamic acid, [2-[[2-[2-(methylamino)ethyl]phenyl]amino]-2-oxoethyl]-, 9H-fluoren-9-ylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



RN 297175-40-7 CAPLUS

CN Carbamic acid, [2-[[2-[2-[methyl[(2R)-2-(methylamino)-3-(2-naphthalenyl)-1-oxopropyl]amino]ethyl]phenyl]amino]-2-oxoethyl]-, 9H-fluoren-9-ylmethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:233909 CAPLUS
DN 130:275757

TI Contrasting agent for infarct and necrosis imaging of heart and kidneys
 IN Platzek, Johannes; Niedballa, Ulrich; Raduchel, Bernd; Ebert, Wolfgang;
 Weinmann, Hanns-Joachim
 PA Schering A.-G., Germany
 SO PCT Int. Appl., 112 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9916757	A1	19990408	WO 1998-EP5184	19980817
	W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	DE 19744003	A1	19990715	DE 1997-19744003	A 19970926
	DE 19744003	B4	20040708	DE 1997-19744003	19970926
	CA 2304458	AA	19990408	CA 1998-2304458	19980817
				DE 1997-19744003	A 19970926
				WO 1998-EP5184	W 19980817
	AU 9893428	A1	19990423	AU 1998-93428	19980817
				DE 1997-19744003	A 19970926
				WO 1998-EP5184	W 19980817
	EP 1017684	A1	20000712	EP 1998-946346	19980817
	EP 1017684	B1	20021120		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
				DE 1997-19744003	A 19970926
				WO 1998-EP5184	W 19980817
	JP 2001518471	T2	20011016	JP 2000-513843	19980817
				DE 1997-19744003	A 19970926
				WO 1998-EP5184	W 19980817
	AT 228116	E	20021215	AT 1998-946346	19980817
				DE 1997-19744003	A 19970926
				WO 1998-EP5184	W 19980817
	PT 1017684	T	20030331	PT 1998-946346	19980817
				DE 1997-19744003	A 19970926
	ES 2188011	T3	20030616	ES 1998-946346	19980817
				DE 1997-19744003	A 19970926
	US 6083479	A	20000704	US 1998-157959	19980922
				DE 1997-19744003	A 19970926
	NO 2000001556	A	20000523	NO 2000-1556	20000324
				DE 1997-19744003	A 19970926
				WO 1998-EP5184	W 19980817

OS MARPAT 130:275757

AB 1,4,7,10-Tetraazacyclododecane derivs. and their rare earth complexes as novel compds. suitable as contrasting agents, in particular for infarct and necrosis imaging, are disclosed, as well as processes for preparing the same and pharmaceuticals containing these compds. Thus, sym-diethylenetriaminepentaacetic acid tetra-tert-Bu ester in presence of N-hydroxysuccinimide in DMF was treated with dicyclohexylcardodimide and subsequently with glycine in presence of Et3N to give 3,9-bis(N-tert-butoxycarbonylmethyl)-6-[N-(3-aza-2-oxo-4-carboxy)butyl]-3,6,9-triazaundecane-1,11-dicarboxylic acid di-tert-Bu ester (I). I was reacted with 1,4,7,10-tetraazacyclododecane in DMF in presence of

2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline to give 1,4,7-tris{3,9-bis(N-tert-butoxycarbonylmethyl)-6-[N-(3-aza-2,5-dioxo)pentan-1,5-diyl]-3,6,9-triazaundecanedicarboxylic di-tert-Bu ester}-1,4,7,10-tetraazacyclododecane which was reacted with hexadecanoic acid in DMF to give 1,4,7-tris{3,9-bis(N-tert-butoxycarbonylmethyl)-6-[N-(3-aza-2,5-dioxo)pentan-1,5-diyl]-3,6,9-triazaundecanedicarboxylic di-tert-Bu ester}-10-[N-n-hexadecanoyl]-1,4,7,10-tetraazacyclododecane (II). II in CF₃CO₂H reacted with Gd₂O₃ in presence of NaOH to give after deprotection the Na salt of the Gd complex of the deprotected II.


IT 192636-26-3P 192636-28-5P 222033-44-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(reactant for preparation of rare earth complexes with alkylcarbonyl derivs. of tetraazacyclododecane as MRI contrast agents for myocardial infarction and renal ischemia)


RN 192636-26-3 CAPLUS



CN Benzoic acid, 3,5-bis[[[(phenylmethoxy)carbonyl]amino]acetyl]amino]-(9CI) (CA INDEX NAME)






RN 192636-28-5 CAPLUS

CN Carbamic acid, [1,4,7,10-tetraazacyclododecane-1,4,7-triyltris[carbonyl-5,1,3-benzenetriylbis[imino(2-oxo-2,1-ethanediyl)]]]hexakis-, hexakis(phenylmethyl) ester (9CI) (CA INDEX NAME)





CN Carbamic acid, [[10-(1-oxotetradecyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl]tris[carbonyl-5,1,3-benzenetriylbis[imino(2-oxo-2,1-ethanediyl)]]]hexakis-, hexakis(phenylmethyl) ester (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:268469 CAPLUS
DN 129:16384
TI Preparation of novel pyrrolidine derivatives as remedies for infectious diseases
IN Ohta, Toshiharu; Nakayama, Kiyoshi; Ohtsuka, Masami; Inagaki, Hiroaki; Nishi, Toshiyuki; Ishida, Yohhei
PA Daiichi Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 164 pp.
CODEN: PIXXD2
DT Patent
LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9817625	A1	19980430	WO 1997-JP3812	19971022
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, ID, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
			JP 1996-279172	19961022
			JP 1996-287203	19961030
AU 9747221	A1	19980515	AU 1997-47221	19971022
			JP 1996-279172	19961022
			JP 1996-287203	19961030
			WO 1997-JP3812	19971022

OS MARPAT 129:16384

AB Novel compds. (I; R1-R3 = substituents in the cyclic structure, such as a pyrrolidine or a benzene ring; A = hydrocarbon or heterocyclo ring) are prepared I act on pathogenic microorganisms which have acquired tolerance to the existing antimicrobials and elevate the sensitivity to the antimicrobials, thus making them nontolerant. When used together with the

antimicrobials, I can efficaciously establish the prevention and treatment of microbial infectious diseases. Thus, compound (II; X = tert-BuCO, Y = N3) (preparation given) was hydrogenated over Pd/C to give 95% the title compound

II.2HCl (X = H, Y = NH₂), which was tested and showed inhibitory activity against PAM1001.

IT 207305-10-0P 207305-14-4P 207305-15-5P

207305-17-7P 207305-18-8P 207305-26-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of novel pyrrolidine derivs. as remedies for infectious diseases)

RN 207305-10-0 CAPLUS

CN Carbamic acid, [2-[[3-[[2,2-diphenylethyl]amino]carbonyl]-5-[[2S]-1-oxo-3-phenyl-2-[[phenylmethoxy]carbonyl]amino]propyl]amino]phenyl]amino]-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 207305-14-4 CAPLUS

CN Carbamic acid, [2-oxo-2-[[5-[[2S]-1-oxo-3-phenyl-2-[[phenylmethoxy]carbonyl]amino]propyl]amino]-3-[[3-phenylpropyl]amino]carbonyl]phenyl]amino]ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 207305-15-5 CAPLUS

CN Carbamic acid, [(1S)-2-oxo-2-[[3-[[1-oxo-3-[[(phenylmethoxy) carbonyl] amino]propyl]amino]-5-[[(3-phenylpropyl) amino] carbonyl]phenyl]amino]-1-(phenylmethyl)ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 207305-17-7 CAPLUS

CN Carbamic acid, [2-oxo-2-[[5-[[(2S)-1-oxo-4-phenyl-2-[[(phenylmethoxy) carbonyl] amino]butyl]amino]-3-[[(3-phenylpropyl) amino] carbonyl]phenyl]amino]ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 207305-18-8 CAPLUS

CN Carbamic acid, [3-oxo-3-[[3-[[(2S)-1-oxo-4-phenyl-2-[[(phenylmethoxy) carbonyl] amino]butyl]amino]-5-[[(3-phenylpropyl) amino] carbonyl]phenyl]amino]propyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 207305-26-8 CAPLUS

CN Carbamic acid, [2-[[4-[[[(2,2-diphenylethyl)amino]carbonyl]-3-[[[(2S)-1-oxo-3-phenyl-2-[[[(phenylmethoxy)carbonyl]amino]propyl]amino]phenyl]amino]-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1998:87706 CAPLUS

DN 128:154388

TI Preparation of peptide analogs with growth hormone releasing properties

IN Peschke, Bernd; Ankersen, Michael; Hansen, Thomas Kruse; Thogersen, Henning

PA Novo Nordisk A/S, Den.; Peschke, Bernd; Ankersen, Michael; Hansen, Thomas Kruse; Thogersen, Henning

SO PCT Int. Appl., 178 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9803473	A1	19980129	WO 1997-DK314	19970717
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,				

DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9734346	A1	19980210	DK 1996-803	A	19960722
			AU 1997-34346		19970717
			DK 1996-803	A	19960722
EP 923539	A1	19990623	WO 1997-DK314	W	19970717
EP 923539	B1	20020605	EP 1997-930368		19970717
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
			DK 1996-803	A	19960722
			WO 1997-DK314	W	19970717
US 5922770	A	19990713	US 1997-896550		19970717
			DK 1996-803	A	19960722
JP 2000515517	T2	20001121	JP 1998-506465		19970717
			DK 1996-803	A	19960722
			WO 1997-DK314	W	19970717
EP 1184370	A2	20020306	EP 2001-123155		19970717
EP 1184370	A3	20020327			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
			DK 1996-803	A	19960722
			EP 1997-930368	A3	19970717
AT 218537	E	20020615	AT 1997-930368		19970717
			DK 1996-803	A	19960722
			WO 1997-DK314	W	19970717
ZA 9706371	A	19980122	ZA 1997-6371		19970718
			DK 1996-803	A	19960722
US 6127354	A	20001003	US 1999-270862		19990317
			DK 1996-803	A	19960722
			US 1997-896550	A3	19970717
US 6274584	B1	20010814	US 2000-619227		20000719
			DK 1996-803	A	19960722
			US 1997-896550	A3	19970717
			US 1999-270862	A3	19990317

OS MARPAT 128:154388

AB The present invention relates to novel peptide analogs of general formula I [A = X-A1; X = alkylene chain optionally substituted and/or optionally containing O, S, or C:C double bond; A1 = N-containing heterocycle, (aminoalkyl)phenyl, (aminoalkyl)thienyl; G = H, halo, C1-6 alkyl, aryl, C1-6 alkoxy, CONR39R40, (CH2)pNR39SO2R41, (CH2)pNR39COR40, (CH2)pOR41, (CH2)pO2CR40, CHR39R40, CONR39NR40R42, (CH2)pNR39CSNR40R42, (CH2)pNR39CONR40R42; R39, R40 = independently H, (un)substituted C1-6 alkyl, etc.; R41 = aryl-substituted C1-6 alkyl; R42 = C1-6 alkyl; L1, L2 = independently CR57, N; R57 = H, C1-6 alkyl (un)substituted with OH, halo, C1-6 alkoxy, aryl; D, E = independently H, alkoxy, aryl, heteroaryl; R1 = H, C1-6 alkyl; R2 = H, acyl, C1-6 alkyl; R1R2 may form alkylene bridge; R3, R4 = independently H, (un)substituted C1-6 alkyl; R3R4 = O, S; n, m, p = independently 0-3] pharmaceutical compns. containing them, a method of stimulating the release of growth hormone from the pituitary, a method for increasing the rate and extent of growth of animals to increase their milk and wool production, or for the treatment of ailments, and to use of the compds. for the preparation of medicaments. Thus, peptidomimetic II was prepared

by standard reactions from (R)-2-[N-tert-butoxycarbonyl-N-methylamino]-3-(2-naphthyl)propionic acid, N-methyl-N-phenethylamine, and (E)-5-(tert-butoxycarbonylamino)-5-methylhex-2-enoic acid. II and related peptide analogs were tested for growth hormone release in rat pituitary primary cultures in doses ranging from 10 pM to 100 mM. The prepared compds. were also tested for metabolic stability.

IT 202811-34-5P 202811-35-6P 202811-36-7P


202811-37-8P 202811-38-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of peptide analogs with growth hormone releasing properties)


RN 202811-34-5 CAPLUS

CN Carbamic acid, [2-[2-[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]acetyl]amino]phenyl]ethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 202811-35-6 CAPLUS

CN Carbamic acid, [2-[[2-[2-(methylamino)ethyl]phenyl]amino]-2-oxoethyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)




RN 202811-36-7 CAPLUS
 CN Carbamic acid, [(1R)-2-[[2-[2-[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]acetyl]amino]phenyl]ethyl]methylamino]-1-(2-naphthalenylmethyl)-2-oxoethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 202811-37-8 CAPLUS
 CN Carbamic acid, [2-[[2-[2-[methyl[2-(methylamino)-3-(2-naphthalenyl)-1-oxopropyl]amino]ethyl]phenyl]amino]-2-oxoethyl]-, 9H-fluoren-9-ylmethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 202811-38-9 CAPLUS

CN Carbamic acid, [(3E)-5-[[[(1R)-2-[[2-[2-[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]acetyl]amino]phenyl]ethyl]methylamino]-1-(2-naphthalenylmethyl)-2-oxoethyl]methylamino]-1,1-dimethyl-5-oxo-3-pentenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A





RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:500179 CAPLUS
DN 127:122137
TI Nitrogen-containing cascade polymer transition metal complexes and their
manufacture and use in pharmaceuticals and diagnostic agents
IN Schmitt-Willich, Heribert; Platzek, Johannes; Raduechel, Bernd; Weinmann,
Hanns joachim; Ebert, Wolfgang; Misselwitz, Bernd; Muehler, Andreas;
Frenzel, Thomas
PA Schering A.-G., Germany
SO Ger. Offen., 51 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19549286	A1	19970626	DE 1995-19549286	19951222
	CA 2241187	AA	19970703	CA 1996-2241187	19961129
				DE 1995-19549286	A 19951222
	WO 9723245	A1	19970703	WO 1996-EP5315	19961129
	W: AU, BG, BY, CA, CZ, IL, JP, KR, MX, NO, NZ, PL, RU, SK, UA, US, VN				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
				DE 1995-19549286	A 19951222
	AU 9710328	A1	19970717	AU 1997-10328	19961129
	AU 726034	B2	20001026		
				DE 1995-19549286	A 19951222
				WO 1996-EP5315	W 19961129
	EP 868202	A1	19981007	EP 1996-941055	19961129
	EP 868202	B1	20020828		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
				DE 1995-19549286	A 19951222
				WO 1996-EP5315	W 19961129
	JP 2000510880	T2	20000822	JP 1997-523251	19961129
				DE 1995-19549286	A 19951222
				WO 1996-EP5315	W 19961129

AT 222776	E	20020915	AT 1996-941055	19961129
			DE 1995-19549286	A 19951222
			WO 1996-EP5315	W 19961129
RU 2197495	C2	20030127	RU 1998-113782	19961129
			DE 1995-19549286	A 19951222
			WO 1996-EP5315	W 19961129
PT 868202	T	20030131	PT 1996-941055	19961129
			DE 1995-19549286	A 19951222
ES 2181924	T3	20030301	ES 1996-941055	19961129
			DE 1995-19549286	A 19951222
SK 283334	B6	20030603	SK 1998-854	19961129
			DE 1995-19549286	A 19951222
			WO 1996-EP5315	W 19961129
ZA 9610822	A	19970627	ZA 1996-10822	19961220
			DE 1995-19549286	A 19951222
US 5874061	A	19990223	US 1996-777666	19961220
			DE 1995-19549286	A 19951222
TW 520377	B	20030211	TW 1996-85115801	19961220
			DE 1995-19549286	A 19951222
US 6057419	A	20000502	US 1998-77773	19980604
			DE 1995-19549286	A 19951222
			WO 1996-EP5315	W 19961129
BG 63105	B1	20010430	BG 1998-102565	19980619
			DE 1995-19549286	A 19951222
			WO 1996-EP5315	W 19961129
NO 9802903	A	19980622	NO 1998-2903	19980622
			DE 1995-19549286	A 19951222
			WO 1996-EP5315	W 19961129
AU 744292	B2	20020221	AU 2000-55021	20000830
AU 2000055021	A5	20001109		


DE 1995-19549286 A 19951222

AB Complexes containing (a) A[X[Y[Z(WKw)z]y]x]a ligands (A = N-containing cascade polymer core with a branching degree, X, Y = direct bond or repeating unit with branching degree x, y, resp., Z, W = repeating unit with branching degree z, w, resp., K = complex formers, a = 2-12, x, y, z, w = 1-4, ≥ 2 repeating units being different, $16 \leq axyzw \leq 64$, and ≥ 1 of X, Y, Z, W being a 1,4,7,10-tetraazacyclododecane or 1,4,8,11-tetraazacyclotetradecane repeating unit), (b) ≥ 16 ions of metals with atom. nos. 20-29, 39, 42, 44, or 57-83, (c) optionally, an cation of (in)organic base, amino acid, or amino amide, and (d) optionally, acylated terminal amino group are are manufactured for use as pharmaceuticals and contrast agents in NMR tomog. and radiog. A typical complex was manufactured by reaction of HBr with benzyloxycarbonyl-blocked 36mer cascade polyamine prepared from N,N,N',N',N'',N'''-hexakis(2-aminoethyl)trimesic acid core and 6 1-[5-(4-nitrophenoxy)-3-oxaglutaryl]-4,7,10-tris(N,N'-dibenzoyloxycarbonyllysyl)-1,4,7,10-tetraazacyclododecane, reaction of the resulting 36-mer amine hydrobromide with 1-(3-aza-4-carboxy-2-oxobutyl)-4,7,10-tris(tert-butoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane, and complexation of the Na salt of the resulting ligand with Gd2O3.


IT 192636-26-3P 192636-27-4P 192636-28-5P
192636-29-6P
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(cascade polymer precursor; nitrogen-containing cascade polymer transition metal complexes and their manufacture and use in pharmaceuticals and diagnostic agents)

RN 192636-26-3 CAPLUS

CN Benzoic acid, 3,5-bis[[[(phenylmethoxy)carbonyl]amino]acetyl]amino]-
(9CI) (CA INDEX NAME)







RN 192636-27-4 CAPLUS
 CN Carbamic acid, [[5-[[[(2,5-dioxo-1-pyrrolidinyl)oxy]carbonyl]-1,3-phenylene]bis[imino(2-oxo-2,1-ethanediyl)]]bis-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)



RN 192636-28-5 CAPLUS
 CN Carbamic acid, [1,4,7,10-tetraazacyclododecane-1,4,7-triyltris[carbonyl-5,1,3-benzenetriylbis[imino(2-oxo-2,1-ethanediyl)]]]hexakis-, hexakis(phenylmethyl) ester (9CI) (CA INDEX NAME)


PAGE 1-A








RN 192636-29-6 CAPLUS

CN Acetic acid, [2-oxo-2-[4,7,10-tris[3,5-bis[[[(phenylmethoxy)carbonyl]amino]acetyl]amino]benzoyl]-1,4,7,10-tetraazacyclododec-1-yl]ethoxy]- (9CI)
(CA INDEX NAME)





IT 192636-30-9P

RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)

(complexing cascade polymer precursor; nitrogen-containing cascade polymer transition metal complexes and their manufacture and use in pharmaceuticals and diagnostic agents)


RN 192636-30-9 CAPLUS




Acetic acid, [2-oxo-2-[4,7,10-tris[3,5-bis[[[(phenylmethoxy)carbonyl]amino]acetyl]amino]benzoyl]-1,4,7,10-tetraazacyclododec-1-yl]ethoxy]-, polymer with N,N,N',N',N'',N''-hexakis(2-aminoethyl)-1,3,5-benzenetricarboxamide hydrobromide (9CI) (CA INDEX NAME)

CM 1

CRN 192636-29-6

CMF C93 H96 N16 025






CM 2

CRN 192635-87-3

CMF C21 H39 N9 O3 . x Br H



●x HBr

IT 192636-31-0DP, gadolinium complexes

RL: IMF (Industrial manufacture); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)

(nitrogen-containing cascade polymer transition metal complexes and their manufacture and use in pharmaceuticals and diagnostic agents)

RN 192636-31-0 CAPLUS


CN Sodium(1+), [tris(1,1-dimethylethyl) 10-[1-methyl-2-[[2-(4-nitrophenoxy)-2-oxoethyl]amino]-2-oxoethyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetate-κN1,κN4,κN7,κN10]-, bromide, polymer with N,N,N',N',N'',N''-hexakis(2-aminoethyl)-1,3,5-benzenetricarboxamide hydrobromide and [2-oxo-2-[4,7,10-tris[3,5-bis[[[(phenylmethoxy) carbonyl] amino]acetyl]amino]benzoyl]-1,4,7,10-tetraazacyclododec-1-yl]ethoxy]acetic acid (9CI) (CA INDEX NAME)

CM 1




CRN 192636-29-6

CMF C93 H96 N16 O25

PAGE 1-A



PAGE 1-B




CM 2

CRN 192636-00-3

CMF C37 H60 N6 Na O11 . Br

CCI CCS




● Br⁻

CM 3

CRN 192635-87-3

CMF C21 H39 N9 O3 . x Br H



● x HBr

L4 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1995:32622 CAPLUS

DN 122:31918

TI Structure-activity relationships of double-strand RGD peptides as GPIIb/IIIa receptor antagonists

AU Ojima, Iwao; Dong, Qing; Eguchi, Masakatsu; Oh, Young-im; Amann, Clare M.; Collier, Barry S.

CS School. Medicine, State University New York, Stony Brook, NY, 11794, USA

SO Bioorganic & Medicinal Chemistry Letters (1994), 4(14), 1749-54

CODEN: BMCLE8; ISSN: 0960-894X

DT Journal

LA English

AB A series of new double-strand RGD peptides M(CO-Arg-Gly-Asp-Phe-OH)₂ [M = (CH₂)_n, p-C₆H₄, n = 2-4] and (R-Arg-Gly-Asp-Phe-NH)₂XZ [R = H, Me(CH₂)₄CO, Bz, 4-[HN:C(NH₂)NH]C₆H₄CO-Ser; X = Lys, Orn, cis,cis-3,5-diaminocyclohexanecarbonyl, 3,5-(Gly-NH)₂C₆H₃CO; Z = NH₂, Gly-Arg-Gly-Asp-Phe-NH₂, Arg-Gly-Asp-Phe-OH] were prepared and their inhibitory activities evaluated for platelet aggregation. Substantial


improvement in activity is observed with these novel RGD peptides in comparison with single-strand RGD peptides. The structure-activity relationships of these double-strand RGD peptides are discussed.

IT **159581-70-1P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, deblocking, and peptide coupling of, with protected arginylglycylaspartic acid peptides)

RN 159581-70-1 CAPLUS

CN Benzoic acid, 3,5-bis[[[(9H-fluoren-9-ylmethoxy) carbonyl]amino]acetyl]amino]- (9CI) (CA INDEX NAME)



L4 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1992:58986 CAPLUS

DN 116:58986

TI Preparation of anilide derivatives for determination of enzymes

IN Hamada, Yoshio; Tejima, Shinichi; Hanyu, Tsuneo

PA Toyobo Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 10 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 03157353	A2	19910705	JP 1989-296592	19891115
	JP 07051550	B4	19950605		
				JP 1989-296592	19891115

OS MARPAT 116:58986

AB Anilides derivs. [I; R1 = amino acid or peptide residue containing 2-4 amino acid; R2 = C1-3 alkyl; R3 = C1-5 alkyl; X = organic or inorg. acid residue; X1-X4 = H, alkyl, aryl, halo, NO2, CO2H; n = 1-6], useful in determining leucine


aminopeptidase and γ -glutamyl transpeptidase (δ -GTP) for diagnosis purposes, are prepared Refluxing a mixture of p-FC6H4NO2, Me2NCH2CH2NH2, and K2CO3 in DMF gave 86.8% p-O2NC6H4N(CH2CH2NMe2)Et, which was reduced with SnCl4 in HCl and EtOH to give 95% p-H2NC6H4N(CH2CH2NMe2)Et (II). Reaction of II with Z-Glu-OBzl, Et3N, and ClCO2CH2CHMe2 in THF gave 62.3% anilide III, which was quaternized with MeI to give 98% III.MeI. The quaternary ammonium salt was treated with CF3CO2H, CF3SO3SiMe3, m-cresol, and PhSMe to give a synthetic substrate for determination of γ -GTP.

IT **137214-52-9P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and quaternization of)


RN 137214-52-9 CAPLUS
 CN Carbamic acid, [4-[(aminoiminomethyl)amino]-1-[[[4-[[2-(dimethylamino)ethyl]ethylamino]phenyl]amino]carbonyl]butyl]-, (4-methoxyphenyl)methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 137214-57-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and quaternization of, with Me iodide)
 RN 137214-57-4 CAPLUS
 CN Carbamic acid, [1-[[[4-[[2-(dimethylamino)ethyl]ethylamino]phenyl]amino]carbonyl]-3-methylbutyl]-, phenylmethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 137214-58-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and salt formation of, with trifluoroacetic acid)
 RN 137214-58-5 CAPLUS
 CN Ethanaminium, 2-[ethyl[4-[[4-methyl-1-oxo-2-[(phenylmethoxy)carbonyl]amino]pentyl]amino]phenyl]amino]-N,N,N-trimethyl-, iodide, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● I⁻

L4 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1975:86615 CAPLUS
 DN 82:86615
 TI Intramolecular rearrangements in peptide derivatives of anthranilic acid
 AU Noguchi, Junzo; Kawai, Megumi; Hamada, Masato
 CS Fac. Sci., Hokkaido Univ., Sapporo, Japan
 SO Israel Journal of Chemistry (1974), 12(1-2), 87-101
 CODEN: ISJCAT; ISSN: 0021-2148
 DT Journal
 LA English
 AB The peptidylanthranilic acid ester is stable during peptide coupling. However, the amide bond of peptidylanthranilic acid is catalytically hydrolyzed at pH 7. In this reaction, no decomposition or significant racemization of peptide was observed and the protected peptide was easily obtained. Only glycylanthraniloyl derivs. rearranged into peptide and anthranilic acid in aqueous solution
 IT **55301-22-9P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 55301-22-9 CAPLUS
 CN Carbamic acid, [2-oxo-2-[[2-[[[2-[[[(phenylmethoxy)carbonyl]amino]ethyl]amino]carbonyl]phenyl]amino]ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



=>